Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Last trade$423.85
Day change-$0.11 (-0.03%)
Day range$413.75 – $427.05
Volume252,050
Market cap$9.85B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$9.85B
Price / earnings
—
Price / book
15.71×
Price / sales
6.9×
EV / sales
6.78×
EV / EBITDA
-64.03×
Profitability
Earnings per share
-$6.69
Return on assets
-10.84%
Return on equity
-24.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.54×
Current ratio
3.05×
Quick ratio
2.78×
Cash ratio
1.13×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$168.65M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MDGL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$431.27M
$364.25M
$311.34M
$321.08M
$287.27M
$212.8M
$137.25M
$103.32M
Cost of revenue
$0
$0
$26.85M
$0
$0
$0
$4.51M
$0
Gross profit
$431.27M
$364.25M
$284.49M
$321.08M
$287.27M
$212.8M
$132.74M
$103.32M
Selling, general and administrative
$265.71M
$289.38M
$268.52M
$239.98M
$209.12M
$196.86M
$167.88M
$141.22M
Research and development
$71.76M
$91.18M
$108.69M
$116.27M
$174M
$54.08M
$44.17M
$25.65M
Total operating expenses
$375.28M
$420.56M
$377.21M
$380.69M
$401.24M
$260M
$212.05M
$170.32M
Operating income
$55.99M
-$56.31M
-$92.72M
-$59.61M
-$113.98M
-$47.2M
-$79.31M
-$67M
Interest expense
-$8.07M
-$7.94M
-$7.82M
-$8.3M
-$7.45M
-$3.26M
-$3.3M
-$3.5M
Income before taxes
$55.44M
-$57.94M
-$94.39M
-$58.58M
-$114.19M
-$42.28M
-$73.24M
-$59.42M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$55.44M
-$57.94M
-$94.39M
-$58.58M
-$114.19M
-$42.28M
-$73.24M
-$59.42M
Net income attributable to common shareholders
$55.44M
-$57.94M
-$94.39M
-$58.58M
-$114.19M
-$42.28M
-$73.24M
-$59.42M
EBITDA
$56.38M
-$55.93M
-$92.34M
-$59.22M
-$113.62M
-$46.83M
-$78.93M
-$66.63M
Basic earnings per share
$1.90
-$1.99
-$3.25
-$11.93
-$4.01
-$1.50
-$2.61
-$2.71
Diluted earnings per share
$1.83
-$1.99
-$3.25
-$11.93
-$4.01
-$1.50
-$2.61
-$2.71
Recent news
Company coverage with links to the original publishers.
Kessler Topaz Meltzer & Check, LLP is investigating Madrigal Pharmaceuticals for potential securities law violations following a whistleblower complaint filed by the company's former Senior Vice President of Clinical Development. The complaint alleges that Madrigal suppressed adverse liver-injury data, presented unreproducible efficacy results, and allowed an unblinded board member to control clinical outcome adjudication for its only approved drug, Rezdiffra. Following the disclosure, Madrigal's stock price fell over 8%.
Law firm Kaplan Fox is investigating Madrigal Pharmaceuticals for potential securities violations following a whistleblower complaint filed by a former employee alleging retaliation under Sarbanes-Oxley Act provisions. The complaint concerns data and reporting practices. Madrigal's stock declined 8.08% on November 3, 2026, following the disclosure in the company's Form 10-Q filing.
Law firm Kaplan Fox is investigating Madrigal Pharmaceuticals following a whistleblower complaint filed by a former employee alleging retaliation under Sarbanes-Oxley Act provisions. The complaint concerns data and reporting practices. Madrigal's stock declined 8.08% on November 3, 2026, following the disclosure in the company's Form 10-Q filing.
Zacks highlights four commercial-stage biotechnology companies demonstrating strong revenue growth and market penetration: TG Therapeutics (Briumvi for MS), BioCryst Pharmaceuticals (Orladeyo for HAE), Insmed (Brinsupri and Arikayce for respiratory diseases), and Madrigal Pharmaceuticals (Rezdiffra for MASH). All four companies show consistent quarterly sales increases, expanding patient adoption, and strategic initiatives to broaden their commercial reach through new formulations, international expansion, and label expansions.
Law firm Hagens Berman has launched an investigation into Madrigal Pharmaceuticals following whistleblower allegations of clinical data integrity issues with its drug Rezdiffra. Former SVP Dr. Michael Charlton filed complaints alleging suppression of adverse safety events, discrepancies in efficacy data, and improper board oversight. The disclosure triggered an 8% stock price decline.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.